Answers are grounded in this paper and cite their sources.
Evaluates molecular class differences in endometrial carcinoma, suggesting directions for future research.
Claims about regulatory differences among endometrial carcinoma molecular classes must distinguish association, target-set robustness, and cross-cohort transportability. We evaluated a fetal Müllerian epithelial module and 20 prespecified developmental transcription-factor regulons in 507 TCGA-UCEC tumours and assessed six signals in 230 CPTAC-UCEC tumours. The global fetal module was non-confirmatory. GATA2 and SOX9 showed negative POLE-plus-MMRd versus NSMP effects in TCGA and the same direction in both CPTAC strata, but neither passed the universal single-target-deletion gate. HOXA9 and WT1 lacked external confirmation, while PAX8 and LHX1 were internally robust but externally unresolved. The evidence supports cross-cohort directional concordance for selected regulons while keeping pointwise association, target-set robustness, and transportability as separate claims. It does not establish biomarker validity, causal transcription-factor activity, therapeutic dependence, treatment response, or clinical utility. The computational and reproducibility record corresponding to this preprint is archived as GitHub release v1.0.1 at https://doi.org/10.5281/zenodo.21762178.
No takes yet. Share an insight, caveat, or question.
Toncheva et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: